Anbio Biotechnology (NNNN)

Anbio Biotechnology Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	8.19	6.71	23.54	4.43
Revenue Growth (YoY)	21.95%	-71.49%	431.67%	-
Cost of Revenue	2.3	3.35	10.98	1.89
Gross Profit	5.89	3.36	12.56	2.54
Selling, General & Admin	3.44	1.27	2.17	0.09
Research & Development	0.45	0.13	0.2	-
Operating Expenses	3.89	1.4	2.37	0.09
Operating Income	2	1.96	10.2	2.46
Interest Expense	-	-	-0.01	-
Interest & Investment Income	0.34	0.17	0.04	-
Currency Exchange Gain (Loss)	0.02	0.12	-0.26	-0
Other Non Operating Income (Expenses)	0.02	0.01	0.04	0.08
Pretax Income	2.37	2.25	10.01	2.54
Net Income	2.37	2.25	10.01	2.54
Net Income to Common	2.37	2.25	10.01	2.54
Net Income Growth	5.29%	-77.49%	294.79%	-
Shares Outstanding (Basic)	42	21	-	-
Shares Outstanding (Diluted)	42	21	-	-
Shares Change (YoY)	97.30%	-	-	-
EPS (Basic)	0.06	0.11	-	-
EPS (Diluted)	0.06	0.11	-	-
EPS Growth	-46.63%	-	-	-
Gross Margin	71.90%	50.07%	53.36%	57.40%
Operating Margin	24.38%	29.22%	43.30%	55.46%
Profit Margin	28.99%	33.58%	42.52%	57.26%
EBIT	2	1.96	10.2	2.46
EBIT Margin	24.38%	29.22%	43.30%	55.46%
Revenue as Reported	8.19	6.71	23.54	4.43

Updated Dec 31, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q